Sarah Kim, MD
Gynecologic Oncology · Philadelphia, PANPI 1861547804
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Intuitive Surgical at 40.4% of the total.
Across 38 payments — averaging $356.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Boston Scientific$5K
- AstraZeneca$3K
- Merck$437
- Medtronic$87
- Medical Device Business Services, Inc.$34
- plus $33 from 2 others
Across 8 payments — averaging $14,327 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$61K
- GSK$54K
What the payments were for
- Consulting fees$6,94051%
- Travel & lodging$4,69335%
- Food & beverage$1,87414%
- Education$220%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $5,475 |
| Boston Scientific | 5 | $4,733 |
| AstraZeneca | 1 | $2,740 |
| Merck | 4 | $437 |
| Medtronic | 1 | $87 |
| Medical Device Business Services, Inc. | 2 | $34 |
| Eisai Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,941
- GENERAL UTERINE TISSUE REMOVAL$4,200
- LYNPARZA$2,740
- GENERAL - THERAPIES$487
How this compares
$13,538 in reported general payments places this provider in the 80th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imiquimod | 21 | $3,352 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Philadelphia
- Emily KoPhiladelphia$78K
- Anna SmithPhiladelphia$77K
- Robert BurgerPhiladelphia$59K
- Stephanie KingPhiladelphia$17K
- Fiona SimpkinsPhiladelphia$11K
- Ashley HaggertyPhiladelphia$8K
- Janos TanyiPhiladelphia$3K
- Lea MoukarzelPhiladelphia$3K
- Charlotte MarcusPhiladelphia$660
- Camille McCallisterPhiladelphia$466
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.